NeoTX
is a Biopharmaceutical Company developing anti-cancer immunotherapies

Learn More

Executive Summary

NeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.

Management

Asher Nathan

ASHER NATHAN PhD

CEO

Dr. Asher Nathan has extensive biotech operating experience, having started biotech companies, Intelligene and ...

Read more
Marcel Rozencweig M.D.

MARCEL ROZENCWEIG M.D.

CMO

Dr. Rozencweig is a medical oncologist with more than 40 years of experience and accumulated expertise in clinical trials and...

Read more
Ramona Lloyd PhD

RAMONA LLOYD PhD R.A.C.

COO

Dr. Lloyd is a leading regulatory expert with over 20 years of experience in global regulatory affairs and quality assurance. ...

Read more
Robert Harow

ROBERT HAROW

CFO

Prior to co-founding NeoTX, Mr. Harow co-founded Zoticon Bioventures, where ...

Read more
Roger Kornberg PhD

ROGER KORNBERG PhD

CSO

Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the process by which genetic information ...

Read more
Dr. Michal Shahar

MICHAL SHAHAR PhD

VP of R&D

Dr. Shahar previously served as VP of Research and Development at Efranat Ltd., an immuno-oncology drug ...

Read more

Pipeline

NeoTX is building a pipeline of differentiated cancer immunotherapies

ANYARA
ANYARA is a TTS (Tumor Targeting Superantigen) compound that enhances the ability of the immune system to recognize the tumor. Synergy has been demonstrated in vivo with a combination of ANYARA and a checkpoint inhibitor in an experimental tumor model. The clinical development of ANYARA has principally focused on cancer indications with high unmet medical need. An upcoming clinical trial is planned in combination with a PD-1 inhibitor, a combination strategy supported by the mode of action of ANYARA.
In addition to ANYARA, NeoTX has other programs in immuno-oncology that are in research and development that seek to fill unmet medical needs.

To achieve success, NeoTX’s strategy for growth is to:

  • Discover, acquire and develop technologies that modulate antigen presentation or exploit other mechanisms to enhance the immune system’s ability to attack tumors.
  • Develop business partnerships with ANYARA.
  • Commercialize proprietary products through corporate alliances.
View Press Release

NEWS

October 2016
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

Lund (Sweden) and Tel Aviv (Israel), October 26th 2016 – Active Biotech AB (NASDAQ OMX NORDIC: ACTI) and NeoTX Therapeutics Ltd. announced today that they have entered into a licensing agreement for Active Biotech’s investigational compound Naptomumab estafenatox (“ANYARA”) for cancer immunotherapy. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug. This partnership is a key milestone in NeoTX's strategy to bring tumor recognition enhancing therapeutics to the market.

"We are very enthusiastic about our collaboration with Active Biotech. At NeoTX, we are strongly committed to developing innovative immunotherapies for unmet medical needs. "Active Biotech brings to our collaboration outstanding scientific and intellectual capital, and a powerful commitment to positively impact the treatment of cancer," said Asher Nathan, Chief Executive Officer of NeoTX.

Dr. Marcel Rozencweig, Chief Medical Officer of NeoTX and former Head of Global Clinical Oncology Research at BMS said “We are looking forward to developing ANYARA for immuno-oncology applications. We believe that the ANYARA technology is well suited to increase tumor recognition by the immune system and has demonstrated synergistic activity in combination with checkpoint inhibitors in animal models. As such, ANYARA would be attractive in combination with checkpoint inhibitors whose efficacy can be limited by poor tumor recognition”.

“We are excited about the partnership with NeoTX, who we consider as an ideal partner for ANYARA. This partnership constitutes the next step in the clinical development, as well as the commercialization strategy, for the project.” said Tomas Leanderson, President & CEO of Active Biotech.

About the agreement
Under the terms of the agreement, Active Biotech grants NeoTX exclusive rights to develop and commercialize ANYARA worldwide in cancer indications. The total deal value amounts to $71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech will receive $250 000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.

About ANYARA
ANYARA is a TTS (Tumor Targeting Superantigen) compound that increases the ability of the immune system to recognize the tumor. Synergy has been reported in vivo with a combination of ANYARA and a checkpoint inhibitor in an experimental tumor model. Clinically, the development of ANYARA has primarily been focused on cancer indications with a high unmet medical need. Positive data was reported from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer, where ANYARA was studied both as a single agent (monotherapy) and in combination with an established tumor therapy - docetaxel (Taxotere®) - in patients with advanced cancer. The results showed that ANYARA was well tolerated both as monotherapy and in combination with docetaxel, and increased tumor recognition by T cells.

A Phase 2/3 trial of ANYARA in combination with interferon alpha in renal cell cancer demonstrated acceptable safety but did not meet its primary efficacy endpoint in the ITT population. The upcoming clinical trial will be done in combination with drugs that inhibit checkpoint dampening of the immune system, a combination strategy in line with the mode of action of ANYARA and supported by preclinical data.

NeoTX Therapeutics Ltd. is based in Rehovot Israel and is a clinical stage immuno-oncology company. NeoTX was founded to bring safe and effective immunotherapies to cancer patients. Please visit www.neotx.com for more information.

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington’s disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

For further information, please contact:

NeoTX Therapeutics Ltd.
Asher Nathan CEO
Tel: +1 609 718 2305 x 1

Robert Harow, CFO
Tel: +1 609 718 2305 x 2

(Corp.Reg. No. 515220929)
2 Pekeris Street
Rehovot, Israel
Tel: +1 609 718 2305
Tel: +972 3 912 5853

Active Biotech AB
Tomas Leanderson, President and CEO
Tel: +46 46 19 20 95

Hans Kolam, CFO
Tel: +46 46 19 20 44

(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund, Sweden
Tel: +46 46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 am CET on October 26, 2016.

October 2016 - Rehovot Israel
NeoTX closes $8.8MM Series A funding

NeoTX, an Immuno-Oncology drug development company, has raised over $8,800,000 in Series A funding from investors including Starr Ventures, a fund led by former AIG CEO Hank Greenberg.

Biotech entrepreneur CEO, Dr. Asher Nathan, stated "I am extremely proud of the high quality senior management team we have been able to attract, and the faith that our Series A investors have placed in our ability to succeed. We are extremely excited by the steps we have been able to accomplish early in our existence."

Contact Us

NeoTX
2 Pekeris Street
Rehovot, Israel 7670202
Phone: +1 609 718 2305
Phone: +972 3 912 5853
Fax: +972 8 936 8584

Contact NeoTX

Copyright NeoTX © 2017 | All Rights Reserved